Names | |
---|---|
IUPAC name
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
|
|
Identifiers | |
3D model (Jmol)
|
|
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.044.475 |
EC Number | 248-939-7 |
KEGG | |
MeSH | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
PubChem CID
|
|
UNII | |
|
|
|
|
Properties | |
C12H15N | |
Molar mass | 173.26 g·mol−1 |
Melting point | 40 °C (104 °F; 313 K) |
Boiling point | 128 to 132 °C (262 to 270 °F; 401 to 405 K) 12 Torr |
Slightly soluble | |
Hazards | |
NFPA 704 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
what is ?) | (|
Infobox references | |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a prodrug to the neurotoxin MPP+, which causes permanent symptoms of Parkinson's disease by destroying dopaminergic neurons in the substantia nigra of the brain. It has been used to study disease models in various animal studies.
While MPTP itself has no psychoactive effects, the compound may be accidentally produced during the manufacture of MPPP, a synthetic opioid drug with effects similar to those of morphine and pethidine (meperidine). The Parkinson-inducing effects of MPTP were first discovered following accidental ingestion as a result of contaminated MPPP.
Injection of MPTP causes rapid onset of Parkinsonism, hence users of MPPP contaminated with MPTP will develop these symptoms.
MPTP itself is not toxic, and as a lipophilic compound can cross the blood–brain barrier. Once inside the brain, MPTP is metabolized into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by the enzyme MAO-B of glial cells. MPP+ kills primarily dopamine-producing neurons in a part of the brain called the pars compacta of the substantia nigra. MPP+ interferes with complex I of the electron transport chain, a component of metabolism, which leads to cell death and causes the buildup of free radicals, toxic molecules that contribute further to cell destruction.